Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.44 |
| ▸ | CTSS | P25774 | 7/20 | 0.44 |
| ▸ | CTSL | P07711 | 6/20 | 0.44 |
| ▸ | CTSV | O60911 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 5/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529196 | 1.00 | CTSK (0.44) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5526866 | 0.86 | CTSL (0.45) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5523008 | 0.84 | CTSL (0.44) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5527113 | 0.81 | ALDH1A1 (0.44) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5530243 | 0.81 | CTSL (0.42) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5523062 | 0.80 | CTSS (0.49) | CTSKCTSSCTSLCTSB | |
| SCHEMBL2155645 | 0.80 | CTSK (0.56) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5527445 | 0.79 | CTSL (0.41) | CTSKCTSSCTSLCTSVCTSB | |
| SCHEMBL5528189 | 0.79 | CTSL (0.41) | CTSKCTSSCTSLCTSBEPHX1 | |
| SCHEMBL5533910 | 0.79 | CTSS (0.59) | CTSKCTSSCTSLCTSBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | US | disclosed |
| EP-1178958-B1 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARM INC (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-05-22 | — | — | US | disclosed |
| US-6455502-B1 | Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-09-24 | — | — | US | disclosed |
| EP-1178958-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000055125-A2 | N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096796-A1 | Novel compounds and compositions as protease inhibitors | CTRL, SERPINB1, CPN1 | CTSK 32/4885CTSS 10/4885CTSL 14/4885 |
| US-20070015755-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | CTRL, SERPINB1, CPN1 | CTSK 32/4885CTSS 10/4885CTSL 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.